Sublicense Royalties. For each sublicense granted by Licensee, Licensee shall pay to [[Organization A:Organization]] # fourteen percent (14%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder, and # the lesser of # ​ percent (​) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or # the royalty which would be due if Licensee, rather than the sublicensee, had sold the Licensed Product. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any royalties hereunder.

Sublicense Royalties. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to [[Organization A:Organization]] the lesser of # ​ percent (​) of any royalty payments received under such sublicense with respect to sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or # the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product.

Sublicense Royalties. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to [[Organization A:Organization]] the lesser of # ​ percent (​) of any royalty payments received under such sublicense with respect to sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or # the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold the Licensed Product.

During the Royalty Term, Licensee shall pay Juniper royalties based on worldwide Net Sales in each calendar year in accordance with the table below:

For the Medical Field of Use, Licensee agrees to make the following payments to [[Organization A:Organization]]:

Sublicense. Licensee may sublicense the rights granted to it by Licensor under this Agreement to any of its Affiliates without notice to Licensor, and to any Third Party with Licensor’s prior written consent, which shall not be unreasonably withheld or delayed, provided that any Third Party Sublicensee shall have the necessary financial, regulatory and technical capacity to carry out the portion of Licensee’s obligations under this Agreement sublicensed to such Third Party, and further provided that if a Sublicense is granted to an Affiliate pursuant to the foregoing and such Affiliate becomes a non-Affiliate during the term of any such Sublicense, Licensee shall provide prompt written notice to Licensor of such change of such Sublicensee’s status to non-Affiliate and such non-Affiliate shall only be permitted to continue performance under the applicable Sublicense if approved in writing by Licensor, such approval not to be unreasonably withheld. Any and all Sublicenses shall be subject to the following requirements:

Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to [[Organization A:Organization]] fourteen percent (14%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder.

Sublicense. The foregoing licenses include the right for [[CareDx:Organization]] to allow its subsidiaries (but only for so long as they remain [[CareDx:Organization]] subsidiaries) and any third parties to exercise [[CareDx:Organization]]’s licenses but solely on behalf and for the benefit and account of [[CareDx:Organization]] (provided that if such third party is an acquirer of [[CareDx:Organization]], the obligations of Section 14.5 shall apply). [[CareDx:Organization]] shall be responsible for any acts or omissions of any such subsidiary or third party exercising [[CareDx:Organization]]’s licenses on [[CareDx:Organization]]’s behalf under this Agreement. Subject to the terms and conditions of this Agreement, [[CareDx:Organization]] may sublicense its rights to a subsidiary (but only for so long as it remains a subsidiary of [[CareDx:Organization]]) to the extent necessary for such subsidiary to market, Sell, offer for Sale, import, export, commercialize and otherwise dispose of any Licensed Product; provided that any such sublicense shall be consistent with the terms and conditions of this Agreement and [[CareDx:Organization]] shall be responsible for such sublicensee’s compliance with such terms and shall provide prior written notice and a copy to [[Illumina:Organization]] of such sublicense.

During the Royalty Term, Licensee shall pay Juniper royalties based on worldwide Net Sales in each calendar year in accordance with the table below:

Sublicense. Subject to the terms and conditions set forth herein, [[Merck:Organization]] hereby grants to Dynavax the right to grant Sublicenses (with the right to sublicense through multiple tiers) under the licenses provided in Section 2.1; provided that: